Glenmark Pharmaceuticals has announced the launch of its Airz-FF glycopyrronium/formoterol/fluticasone propionate triple combination inhaler for the treatment of COPD in India. The company said that "AIRZ-FF has been exclusively studied in the Indian population and introduced to address challenges faced by a significant portion of COPD patients in the … [Read more...] about Glenmark launches Airz-FF triple combination inhaler for COPD in India
Business
Iconovo says Amneal will take over development of ICOres-based generic Symbicort
DPI developer Iconovo has announced that Amneal will take over development of a generic version of Symbicort based on Iconovo's multi-dose ICOres device. Iconovo and Amneal initially signed a licensing and development deal in 2016. In March 2019, Iconovo had announced that Mumbai-based CBC Corporation would handle development of the DPI. According to the new … [Read more...] about Iconovo says Amneal will take over development of ICOres-based generic Symbicort
Alnylam and Vir select candidate for development as inhaled COVID-19 vaccine
Alnylam Pharmaceuticals and Vir Biotechnology have announced that they intend to meet with the FDA soon regarding an IND for VIR-2703 (ALN-COV), an inhaled siRNA in development for prevention and/or treatment of COVID-19. The companies said that VIR-2703 may also have activity against other coronaviruses. The collaboration agreement between Vir and Alnylam includes … [Read more...] about Alnylam and Vir select candidate for development as inhaled COVID-19 vaccine
Marinomed gets funding for development of Carragelose inhalation solution for the treatment of COVID-19 pneumonia
Marinomed Biotech has announced new funding from the Austrian Research Promotion Agency (FFG) for development of a Carragelose inhalation solution for COVID-19 pneumonia. The funding is part of the FFG's "Emergency Call to research COVID-19 in the wake of the outbreak of SARS-CoV-2." Carragelose is a polymer derived from red seaweed that has shown activity against … [Read more...] about Marinomed gets funding for development of Carragelose inhalation solution for the treatment of COVID-19 pneumonia
Avalyn Pharma raises $35.5 million for development of inhaled pirfenidone
Avalyn Pharma (formerly Genoa Pharmaceuticals) announced that it has raised $35.5 million in a Series B financing round led by Norwest Venture Partners. The proceeds will fund a Phase 2/3 trial Avalyn's AP01 nebulized pirfenidone for the treatment of chronic lung allograft dysfunction in lung transplant patients. AP01 is also in development for the treatment of … [Read more...] about Avalyn Pharma raises $35.5 million for development of inhaled pirfenidone
Inhalation Sciences sells its remaining shares in spinoff Ziccum
Inhalation Sciences (ISAB) announced that it has sold all of its remaining shares in its spinoff Ziccum AB, a spray drying specialist, for a total of approximately SEK 21.2 million. In May 2019, ISAB announced that it was selling 40,000 shares of Ziccum to finance a study necessary to validate its PreciseInhale dosing system for clinical use. With the sale of the … [Read more...] about Inhalation Sciences sells its remaining shares in spinoff Ziccum
Pulmatrix licenses NasoCalm to Sensory Cloud for an OTC nasal protection product against COVID-19
Tech start-up Sensory Cloud has acquired an exclusive worldwide license for Pulmatrix salt formulations PUR 003 and PUR 006 (NasoCalm), for purposes of "OTC nasal delivery to potentially reduce the pathogenic risk and transmissibility of contagions, including with respect to COVID-19." Sensory Cloud will pay royalties rising from 7% this year to 14% in 2021 and 17% … [Read more...] about Pulmatrix licenses NasoCalm to Sensory Cloud for an OTC nasal protection product against COVID-19
TFF Pharmaceuticals enters agreement with US Army for development of dry powder vaccines
TFF Pharmaceuticals said that it has entered into a 3-year Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for development of dry powder vaccines against alphaviruses such as Eastern equine encephalitis and against filoviruses such as Ebola and Marburg. … [Read more...] about TFF Pharmaceuticals enters agreement with US Army for development of dry powder vaccines
TFF announces collaboration with the University of Georgia and UT Austin on dry powder universal flu vaccine
TFF Pharmaceuticals has announced a research collaboration deal with the University of Georgia’s Center for Vaccines and Immunology (CVI) and with the University of Texas at Austin (UT Austin) for testing of dry powder universal influenza vaccines formulated using TFF's thin film freezing technology. UT Austin will formulate CVI vaccines based on TFF's technology, and … [Read more...] about TFF announces collaboration with the University of Georgia and UT Austin on dry powder universal flu vaccine
Chiesi acquires rights to Third Pole’s tankless iNO delivery system
Third Pole Therapeutics has announced a deal with Chiesi Farmaceutici giving Chiesi global rights to develop and commercialize Third Pole's tankless inhaled nitric oxide (iNO) delivery system for the treatment of infants with hypoxic respiratory failure in neonatal intensive care. Third Pole had previously announced a strategic collaboration agreement with Johnson … [Read more...] about Chiesi acquires rights to Third Pole’s tankless iNO delivery system